Mediwound LTD

Samuel Rubinstein, a Director of MediWound Ltd., reported multiple transactions in common stock on September 1, 2026.

Shmuel Hess, COO & Chief Commercial Officer of MediWound Ltd., sold 5,823 shares of common stock on August 26, 2026.

MediWound Ltd. Director Nachum Shamir has acquired ordinary shares and holds various derivative securities, as detailed in a recent SEC Form 4 filing.

MediWound Ltd. director David Morton Fox reported the acquisition of ordinary shares and the grant of stock options on June 1, 2026.

MediWound Ltd. Director Samuel Rubinstein reported the acquisition of 150 ordinary shares and provided an update on his beneficial ownership of company stock.

Access Industries and its affiliated entities, including Clal Industries, filed an Amendment No. 6 to Schedule 13D, reaffirming their beneficial ownership of 11.56% of MediWound Ltd.'s ordinary shares.

HOLD Alapkezelo Zrt. has filed a Schedule 13G, reporting beneficial ownership of 1,348,323 shares, representing 10.4% of MediWound Ltd.'s common stock outstanding as of June 30, 2026.

T. Rowe Price Associates, Inc. has reported beneficial ownership of 5.5% of MediWound Ltd's common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has reported a 4.3% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.

Hungarian investment fund HOLD Alapkezelo Zrt. has reported a beneficial ownership of 8.1% in MediWound Ltd., holding 1,039,954 common shares.

Rosalind Advisors and related entities have updated their beneficial ownership in MediWound Ltd. to 7.0% of common shares, including warrants subject to a blocker provision.

Yelin Lapidot Holdings Management and its principals have disclosed a 5.95% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.